Providence Capital Advisors’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.14M Buy
79,000
+4,200
+6% +$385K 1.17% 33
2025
Q4
$6.73M Buy
+74,800
New +$7.09M 1.13% 31
2025
Q3
Sell
-65,100
Closed -$5.94M 249
2025
Q2
$5.94M Buy
65,100
+8,700
+15% +$841K 1.09% 41
2025
Q1
$6.38M Buy
56,400
+800
+1% +$85.6K 1.33% 22
2024
Q4
$5.87M Buy
55,600
+2,800
+5% +$300K 1.19% 37
2024
Q3
$5.7M Buy
52,800
+4,191
+9% +$457K 1.13% 42
2024
Q2
$5.28M Buy
48,609
+48,600
+540,000% +$5.73M 1.15% 40
2024
Q1
$1.19K Buy
+9
New +$1.12K ﹤0.01% 311
2019
Q2
Sell
-41
Closed -$5K 295
2019
Q1
$5K Hold
41
﹤0.01% 218
2018
Q4
$4K Hold
41
﹤0.01% 229
2018
Q3
$5K Hold
41
﹤0.01% 234
2018
Q2
$4K Hold
41
﹤0.01% 235
2018
Q1
$4K Hold
41
﹤0.01% 234
2017
Q4
$5K Buy
+41
New +$4.64K ﹤0.01% 268

Other funds holding ZBH

Providence Capital Advisors's ZBH Position: Q1 2026 in Review

Providence Capital Advisors increased its Zimmer Biomet (ZBH) stake by 5.6% in Q1 2026, buying an estimated $385K and bringing the position to 79,000 shares worth $7.14M. The position accounts for 1.17% of the portfolio, ranked #33.

Providence Capital Advisors first reported a position in ZBH in Q4 2017 and has held it in 14 quarters since. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Providence Capital Advisors held 79,000 shares of Zimmer Biomet worth $7.14M as of Q1 2026.
  • Providence Capital Advisors bought 4,200 Zimmer Biomet shares in Q1 2026, an estimated $385K.
  • Zimmer Biomet made up 1.17% of Providence Capital Advisors's portfolio in Q1 2026, its #33 holding.
  • Providence Capital Advisors first reported a position in Zimmer Biomet in Q4 2017 and has held it in 14 quarters since.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Providence Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.